Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Purpose: Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the prognostic value of volume-derived positron-emission tomography (PET) parameters on baseline and follow-up 18 F-fluoro-deoxy-glucose PET ( 18 F-FDG-PET) scans and compare it with the conventional PET Response Criteria in Solid Tumors (PERCIST). Methods: Patients with metastatic NSCLC were included in two different single-center prospective trials. 18 F-FDG-PET studies were performed before the start of immunotherapy (PET baseline ), after 6–8 weeks (PET interim 1) and after 12–16 weeks (PET interim 2) of treatment, using PERCIST criteria for tumor response assessment. Different metabolic parameters were evaluated: absolute values of maximum standardized uptake value (SUVmax) of the most intense lesion, total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), but also their percentage changes between PET studies (ΔSUVmax, ΔTMTV and ΔTLG). The median follow-up of patients was 31 (7.3–31.8) months. Prognostic values and optimal thresholds of PET parameters were estimated by ROC (Receiver Operating Characteristic) curve analysis of 12-month overall survival (12M-OS) and 6-month progression-free survival (6M-PFS). Tumor progression needed to be confirmed by a multidisciplinary tumor board, considering atypical response patterns on imaging. Results: 110 patients were prospectively included. On PET baseline , TMTV was predictive of 12M-OS [AUC (Area Under Curve) =0.64; 95% CI: 0.61 to 0.66] whereas SUVmax and TLG were not. On PET interim 1 and PET interim 2, all metabolic parameters were predictive for 12M-OS and 6M-PFS, the residual TMTV on PET interim 1 (TMTV 1 ) being the strongest prognostic biomarker (AUC=0.83 and 0.82; 95% CI: 0.74 to 0.91, for 12M-OS and 6M-PFS, respectively). Using the optimal threshold by ROC curve to classify patients into three TMTV 1 subgroups (0 cm 3 ; 0–57 cm 3 ; >57 cm 3 ), TMTV 1 prognostic stratification was independent of PERCIST criteria on both PFS and OS, and significantly outperformed them. Subgroup analysis demonstrated that TMTV 1 remained a strong prognostic biomarker of 12M-OS for non-responding patients (p=0.0003) according to PERCIST criteria. In the specific group of patients with PERCIST progression on PET interim 1, low residual tumor volume (<57 cm 3 ) was still associated with a very favorable patients’ outcome (6M-PFS=73%; 24M-OS=55%). Conclusion: The absolute value of residual metabolic tumor volume, assessed 6–8 weeks after the start of ICPI, is an optimal and independent prognostic measure, exceeding and complementing conventional PERCIST criteria. Oncologists should consider it in patients with first tumor progression according to PERCIST criteria, as it helps identify patients who benefit from continued treatment. Trial registration number: 2018-A02116-49; NCT03584334 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Nioche, C., Orlhac, F., Boughdad, S., Reuzé, S., Goya-Outi, J., Robert, C., Pellot-Barakat, C., Soussan, M., Frouin, F., & Buvat, I. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0125 · Cited by 1,167
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Research works printed but not linked: 5
- Seymour, 2017, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, 18, e143, 10.1016/s1470-2045(17)30074-8 · DOI · Paper page
- Nabet, 2020, Noninvasive early identification of therapeutic benefit from immune Checkpoint inhibition, Cell, 183, 363, 10.1016/j.cell.2020.09.001 · DOI · Paper page
- Im, 2013, Usefulness of combined metabolic–volumetric indices of 18F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer, Nucl Med Mol Imaging, 47, 36, 10.1007/s13139-012-0181-5 · DOI
- Driessen, 2022, The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in 18 F-FDG PET scans of patients with classical Hodgkin lymphoma, J Nucl Med, 63, 1424, 10.2967/jnumed.121.263067 · DOI
- Capobianco, 2021, Deep-learning 18F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma, J Nucl Med, 62, 30, 10.2967/jnumed.120.242412 · DOI
Cited by
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 122
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Zheng, J., Xu, S., Wang, G., & Shi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434171 · Cited by 28
Huang, M., Zou, Y., Wang, W., Li, Q., & Tian, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241293364 · Cited by 23
“20,21 The prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) is frequently reported in many cancers, 22–25 as well as in NSCLC patients undergoing surgery, chemotherapy, or radiotherapy.”
BackgroundMolecular PET imaging: Unlocking the secrets of cancer metabolism
Garg, P., Singhal, G., Horne, D. A., Kulkarni, P., Salgia, R., & Singhal, S. S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117202 · Cited by 23
Metadata
- Authors
- Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O.
- Affiliations
- Centre Antoine Lacassagne (FR)
- Centre National de la Recherche Scientifique (FR)
- Princess Grace Hospital Centre (MC)
- Corresponding author
- Tricarico, Pierre
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2024-04
- Volume
- 12
- Issue
- 4
- Pages
- e007628
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC11043703
- OpenAlex
- W4395014773
- Semantic Scholar
- 9766d9be31cd4d12c52c055e1cef2684807ade6d
- Cited by
- 38
- References
- 37
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 3
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- 3IA cote d'azur (ANR-19-P3IA-0002)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- total metabolic tumor volume, 18F-FDG PET/CT, metastatic non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response monitoring, prognostic factors, PERCIST criteria, SUVmax, total lesion glycolysis, overall survival, progression-free survival, treatment response prediction, treatment toxicity prediction, treatment de-escalation
- MeSH terms
- Positron Emission Tomography Computed Tomography, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Fluorodeoxyglucose F18, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. https://app.cochat.ai/papers/10.1136/jitc-2023-007628
- The paper
- Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O. (2024). Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007628
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.